by Stephen Spellman
Stephen Spellman, a leader at CIBMTR and NMDP, shares insights into key trends shaping hematopoietic cell transplantation and cellular therapy. In this video, he highlights how immunobiology...
by ASTCT Talks
In this episode of ASTCT Talks, Dr. Nirali Shah talks with Dr. Cath Bollard as part of the Titans of Transplant series to explore her remarkable career journey and lasting impact on the field of...
by Margy MacMillan
With the United States marking its 250th anniversary this month, I find myself reflecting on this incredible milestone and, similarly, the history of ASTCT and the field we represent. While our...
by Nature Medicine
Findings from a Phase II study suggest that ciltacabtagene autoleucel (cilta-cel), which is thought to be more effective when delivered in earlier disease states, has promise in the setting of...
by Transplantation and Cellular Therapy
Post-transplantation cyclophosphamide (PTCy) is gaining traction as standard prevention against graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (HCT), but...
by Frontiers in Immunology
Irradiating tumors before administering chimeric antigen receptor (CAR) T-cell therapy may boost CAR T-cell infiltration and improve efficacy in solid tumors, researchers report.